HER2/neu

Iz Wikipedije, slobodne enciklopedije
Jump to navigation Jump to search
edit
V-erb-b2 ptičiji eritroblastni leukemijski viralni onkogeni homolog 2

PDB prikaz baziran na 1n8z.
Dostupne strukture
1MFG, 1MFL, 1MW4, 1N8Z, 1OVC, 1QR1, 1S78, 2A91, 2JWA, 2KS1, 2L4K, 3BE1, 3H3B, 3MZW, 3N85, 3PP0, 3RCD, 4GFU, 4HRL, 4HRM, 4HRN
Identifikatori
Simboli ERBB2; CD340; HER-2; HER-2/neu; HER2; MLN 19; NEU; NGL; TKR1
Vanjski ID OMIM164870 MGI95410 HomoloGene3273 GeneCards: ERBB2 Gene
EC broj 2.7.10.1
Pregled RNK izražavanja
PBB GE ERBB2 216836 s at.png
PBB GE ERBB2 210930 s at.png
podaci
Ortolozi
Vrsta Čovek Miš
Entrez 2064 13866
Ensembl ENSG00000141736 ENSMUSG00000062312
UniProt P04626 P70424
Ref. Sekv. (iRNK) NM_001005862 NM_001003817
Ref. Sekv. (protein) NP_001005862 NP_001003817
Lokacija (UCSC) Chr 17:
37.84 - 37.89 Mb
Chr 11:
98.41 - 98.44 Mb
PubMed pretraga [1] [2]

Receptorska tirozinska proteinska kinaza erbB-2 (CD340, klaster diferencijacije 340, proto-onkogen Neu, Erbb2 (glodari), ili ERBB2 (ljudi)) protein je koji je kod ljudi kodiran ERBB2 genom. Ona se često naziva HER2 (od engl. human epidermal growth factor receptor 2) ili HER2/neu.

HER2 je član familije receptora epidermalnih faktora rasta (HER/EGFR/ERBB). Amplifikacija ili prekomerno izražavanje ovog onkogena ima važnu ulogu u razviću i progresiji pojedinih agresivnih tipova raka dojke. Zadnjih godina ovaj protein je postao važan biomarker ili meta u lečenju oko 30% pacijenata sa kancerom dojke.[1][2]

HER2 interakcije[uredi - уреди | uredi izvor]

HER2/neu formira interakcije sa:

Reference[uredi - уреди | uredi izvor]

  1. Mitri Z, Constantine T, O'Regan R (2012). "The HER2 Receptor in Breast Cancer: Pathophysiology, Clinical Use, and New Advances in Therapy". Chemother Res Pract 2012: 743193. PMC 3539433. PMID 23320171. doi:10.1155/2012/743193. 
  2. Burstein HJ (October 2005). "The distinctive nature of HER2-positive breast cancers". N. Engl. J. Med. 353 (16): 1652–4. PMID 16236735. doi:10.1056/NEJMp058197. 
  3. Schroeder JA, Adriance MC, McConnell EJ, Thompson MC, Pockaj B, Gendler SJ (2002). "ErbB-beta-catenin complexes are associated with human infiltrating ductal breast and murine mammary tumor virus (MMTV)-Wnt-1 and MMTV-c-Neu transgenic carcinomas". J. Biol. Chem. 277 (25): 22692–8. PMID 11950845. doi:10.1074/jbc.M201975200. 
  4. Bonvini P, An WG, Rosolen A, Nguyen P, Trepel J, Garcia de Herreros A, Dunach M, Neckers LM (2001). "Geldanamycin abrogates ErbB2 association with proteasome-resistant beta-catenin in melanoma cells, increases beta-catenin-E-cadherin association, and decreases beta-catenin-sensitive transcription". Cancer Res. 61 (4): 1671–7. PMID 11245482. 
  5. Kanai Y, Ochiai A, Shibata T, Oyama T, Ushijima S, Akimoto S, Hirohashi S (1995). "c-erbB-2 gene product directly associates with beta-catenin and plakoglobin". Biochem. Biophys. Res. Commun. 208 (3): 1067–72. PMID 7702605. doi:10.1006/bbrc.1995.1443. 
  6. Huang YZ, Won S, Ali DW, Wang Q, Tanowitz M, Du QS, Pelkey KA, Yang DJ, Xiong WC, Salter MW, Mei L (2000). "Regulation of neuregulin signaling by PSD-95 interacting with ErbB4 at CNS synapses". Neuron 26 (2): 443–55. PMID 10839362. doi:10.1016/s0896-6273(00)81176-9. 
  7. 7,0 7,1 Jaulin-Bastard F, Saito H, Le Bivic A, Ollendorff V, Marchetto S, Birnbaum D, Borg JP (2001). "The ERBB2/HER2 receptor differentially interacts with ERBIN and PICK1 PSD-95/DLG/ZO-1 domain proteins". J. Biol. Chem. 276 (18): 15256–63. PMID 11278603. doi:10.1074/jbc.M010032200. 
  8. Bilder D, Birnbaum D, Borg JP, Bryant P, Huigbretse J, Jansen E, Kennedy MB, Labouesse M, Legouis R, Mechler B, Perrimon N, Petit M, Sinha P (2000). "Collective nomenclature for LAP proteins". Nat. Cell Biol. 2 (7): E114. doi:10.1038/35017119. 
  9. Huang YZ, Zang M, Xiong WC, Luo Z, Mei L (2003). "Erbin suppresses the MAP kinase pathway". J. Biol. Chem. 278 (2): 1108–14. PMID 12379659. doi:10.1074/jbc.M205413200. 
  10. 10,0 10,1 Schulze WX, Deng L, Mann M (2005). "Phosphotyrosine interactome of the ErbB-receptor kinase family". Mol. Syst. Biol. 1: 2005.0008. PMC 1681463. PMID 16729043. doi:10.1038/msb4100012. 
  11. Bourguignon LY, Zhu H, Zhou B, Diedrich F, Singleton PA, Hung MC (2001). "Hyaluronan promotes CD44v3-Vav2 interaction with Grb2-p185(HER2) and induces Rac1 and Ras signaling during ovarian tumor cell migration and growth". J. Biol. Chem. 276 (52): 48679–92. PMID 11606575. doi:10.1074/jbc.M106759200. 
  12. 12,0 12,1 Olayioye MA, Graus-Porta D, Beerli RR, Rohrer J, Gay B, Hynes NE (1998). "ErbB-1 and ErbB-2 acquire distinct signaling properties dependent upon their dimerization partner". Mol. Cell. Biol. 18 (9): 5042–51. PMC 109089. PMID 9710588. 
  13. Xu W, Mimnaugh E, Rosser MF, Nicchitta C, Marcu M, Yarden Y, Neckers L (2001). "Sensitivity of mature Erbb2 to geldanamycin is conferred by its kinase domain and is mediated by the chaperone protein Hsp90". J. Biol. Chem. 276 (5): 3702–8. PMID 11071886. doi:10.1074/jbc.M006864200. 
  14. Jeong JH, An JY, Kwon YT, Li LY, Lee YJ (2008). "Quercetin-induced ubiquitination and down-regulation of Her-2/neu". J. Cell. Biochem. 105 (2): 585–95. PMC 2575035. PMID 18655187. doi:10.1002/jcb.21859. 
  15. Grant SL, Hammacher A, Douglas AM, Goss GA, Mansfield RK, Heath JK, Begley CG (2002). "An unexpected biochemical and functional interaction between gp130 and the EGF receptor family in breast cancer cells". Oncogene 21 (3): 460–74. PMID 11821958. doi:10.1038/sj.onc.1205100. 
  16. Li Y, Yu WH, Ren J, Chen W, Huang L, Kharbanda S, Loda M, Kufe D (2003). "Heregulin targets gamma-catenin to the nucleolus by a mechanism dependent on the DF3/MUC1 oncoprotein". Mol. Cancer Res. 1 (10): 765–75. PMID 12939402. 
  17. Schroeder JA, Thompson MC, Gardner MM, Gendler SJ (2001). "Transgenic MUC1 interacts with epidermal growth factor receptor and correlates with mitogen-activated protein kinase activation in the mouse mammary gland". J. Biol. Chem. 276 (16): 13057–64. PMID 11278868. doi:10.1074/jbc.M011248200. 
  18. Gout I, Dhand R, Panayotou G, Fry MJ, Hiles I, Otsu M, Waterfield MD (1992). "Expression and characterization of the p85 subunit of the phosphatidylinositol 3-kinase complex and a related p85 beta protein by using the baculovirus expression system". Biochem. J. 288 (2): 395–405. PMC 1132024. PMID 1334406. 
  19. Peles E, Levy RB, Or E, Ullrich A, Yarden Y (1991). "Oncogenic forms of the neu/HER2 tyrosine kinase are permanently coupled to phospholipase C gamma". EMBO J. 10 (8): 2077–86. PMC 452891. PMID 1676673. 
  20. Arteaga CL, Johnson MD, Todderud G, Coffey RJ, Carpenter G, Page DL (1991). "Elevated content of the tyrosine kinase substrate phospholipase C-gamma 1 in primary human breast carcinomas". Proc. Natl. Acad. Sci. U.S.A. 88 (23): 10435–9. PMC 52943. PMID 1683701. doi:10.1073/pnas.88.23.10435. 
  21. Wong L, Deb TB, Thompson SA, Wells A, Johnson GR (1999). "A differential requirement for the COOH-terminal region of the epidermal growth factor (EGF) receptor in amphiregulin and EGF mitogenic signaling". J. Biol. Chem. 274 (13): 8900–9. PMID 10085134. doi:10.1074/jbc.274.13.8900. 

Literatura[uredi - уреди | uredi izvor]

  • Ross JS, Fletcher JA, Linette GP et al. (2003). "The Her-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy". Oncologist 8 (4): 307–25. PMID 12897328. doi:10.1634/theoncologist.8-4-307. 
  • Zhou BP, Hung MC (2003). "Dysregulation of cellular signaling by HER2/neu in breast cancer". Semin. Oncol. 30 (5 Suppl 16): 38–48. PMID 14613025. doi:10.1053/j.seminoncol.2003.08.006. 
  • Ménard S, Casalini P, Campiglio M et al. (2005). "Role of HER2/neu in tumor progression and therapy". Cell. Mol. Life Sci. 61 (23): 2965–78. PMID 15583858. doi:10.1007/s00018-004-4277-7. 
  • Becker JC, Muller-Tidow C, Serve H et al. (2006). "Role of receptor tyrosine kinases in gastric cancer: new targets for a selective therapy". World J. Gastroenterol. 12 (21): 3297–305. PMID 16733844. 
  • Laudadio J, Quigley DI, Tubbs R, Wolff DJ (2007). "HER2 testing: a review of detection methodologies and their clinical performance". Expert Rev. Mol. Diagn. 7 (1): 53–64. PMID 17187484. doi:10.1586/14737159.7.1.53. 
  • Bianchi F, Tagliabue E, Ménard S, Campiglio M (2007). "Fhit expression protects against HER2-driven breast tumor development: unraveling the molecular interconnections". Cell Cycle 6 (6): 643–6. PMID 17374991. doi:10.4161/cc.6.6.4033. 
  • Del Bimbo A., Meoni M., Pala P. (2010). "Accurate evaluation of HER-2 amplification in FISH images". Imaging Systems and Techniques (IST), 2010 IEEE International Conference on: 407–10. ISBN 978-1-4244-6492-0. doi:10.1109/IST.2010.5548461. 

Vanjske veze[uredi - уреди | uredi izvor]